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Abstract
Background: We hypothesized that sympathetic nervous system activity (SNSA) is increased and
parasympathetic nervous system activity (PNSA) is decreased during non-rapid eye movement
(NREM) sleep in non-apneic, otherwise healthy, snoring individuals compared to control.
Moreover, we hypothesized that these alterations in snoring individuals would be more evident
during non-snoring than snoring when compared to control.
Methods: To test these hypotheses, heart rate variability was used to measure PNSA and SNSA
in 11 normotensive non-apneic snorers and 12 control subjects before and 7-days after adapting
to nasal continuous positive airway pressure (nCPAP).
Results: Our results showed that SNSA was increased and PNSA was decreased in non-apneic
snorers during NREM compared to control. However, these changes were only evident during the
study in which snoring was eliminated with nCPAP. Conversely, during periods of snoring SNSA
and PNSA were similar to measures obtained from the control group. Additionally, within the
control group, SNSA and PNSA did not vary before and after nCPAP application.
Conclusion: Our findings suggest that long-lasting alterations in autonomic function may exist in
snoring subjects that are otherwise healthy. Moreover, we speculate that because of competing
inputs (i.e. inhibitory versus excitatory inputs) to the autonomic nervous system during snoring,
the full impact of snoring on autonomic function is most evident during non-snoring periods.
Background
Epidemiological findings have suggested that snoring is
an independent risk factor for the development of day-
time hypertension [1-3]. Moreover, studies completed in
normotensive individuals suffering from obstructive sleep
apnea have shown that increases in sympathetic nervous
system activity (SNSA) precede the development of hyper-
tension [4]. Given these findings, we hypothesized that
nocturnal increases in SNSA and decreases in parasympa-
thetic nervous system activity (PNSA) may exist in non-
apneic normotensive snoring individuals. Additionally,
we postulated that the impact of snoring on autonomic
nervous system activity might be most evident during
periods of non-snoring (i.e. either during wakefulness or
during periods of non-snoring during sleep). This latter
postulation was based on findings from humans during
wakefulness [5-7] or sleep [8,9], which showed that
breathing frequency [5-7,9], pattern (i.e. inspiratory and
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expiratory time) [5-7,9] and tidal volume [5,7,8] are
altered in response to either snoring [9], the application of
high frequency oscillations (i.e. simulated snoring) [7,8]
or breathing against an increased airway resistance [5,6].
Moreover, these alterations in breathing are accompanied
by enhanced PNSA [6] or decreased SNSA [10]. Thus, we
postulated that snoring elicits a two-fold response from
the autonomic nervous system. An acute response that
occurs concomitantly with snoring, in which increases in
SNSA and decreases in PNSA may not be clearly evident,
and a longer lasting potentially permanent response in
which increases in SNSA and decreases in PNSA are
unmasked in the absence of snoring. To test these hypoth-
eses, we used the technique of heart rate variability to
measure PNSA and SNSA in non-apneic snorers and con-
trols during non-rapid eye movement (NREM) sleep
before and after the application of nasal continuous posi-
tive airway pressure (nCPAP).
Methods
Eleven self-reported snoring subjects with no known med-
ical conditions and 12 non-snoring control subjects were
recruited from the community. The snoring group was
comprised of 9 males (1 Asian, 1 African-American, 2 His-
panic and 5 Caucasian) and 2 Caucasian females (Table
1). The control group was comprised of 10 males (1 Asian,
1 African-American, 2 Hispanic and 6 Caucasian) and 2
Caucasian females (Table 1). All subjects gave their
informed consent to participate in the study, which was
approved by the Institutional Review Boards of Teachers
College, Columbia University, Wayne State University
and John D. Dingell VA Medical Center.
The snoring and control subjects visited the sleep labora-
tory on three occasions. Twenty-four hours prior to each
occasion the subjects were advised to avoid alcohol and
caffeine. During the first visit to the laboratory, which is
referred to from hereon as the preliminary study, subjects
received a physical examination, which included three
separate measures of blood pressure using a standard mer-
cury sphygmomanometer that were separated by 15 min-
utes. Additionally, subjects completed a general health
questionnaire to confirm the absence of pre-existing med-
ical conditions. Subsequently, subjects completed a sleep
study in order to familiarize themselves with the labora-
tory environment and to confirm that the subjects were
non-apneic snoring or non-snoring individuals. Moreo-
ver, to confirm that subjects were normotensive, beat-to-
beat measures of blood pressure were obtained for 1 hour
during wakefulness and throughout NREM sleep (see Noc-
turnal polysomnography for further details). The blood pres-
sure measures were in addition to the values obtained
during wakefulness using the sphygmomanometer. If sub-
jects suffered from another sleep disorder (i.e. obstructive
sleep apnea, insomnia or upper airway resistance syn-
drome) they were excluded from the study. Individuals
with upper airway resistance syndrome were excluded
because we were interested in investigating the impact of
snoring on heart rate variability independent of excessive
cortical arousal from sleep.
The second study was completed in order to measure the
autonomic variables outlined below during NREM sleep.
This second study will be referred to as Trial 1 from her-
eon. Subsequent to the completion of Trial 1, the snoring
and control subjects adapted to 5 cmH2O of nasal contin-
uous positive airway pressure (nCPAP) for 7 days at
Table 1: Anthropometric and blood pressure measures
Control Snorer
Subject Sex Age BMI MAP Awake MAP NREM Subject Sex Age BMI MAP Awake MAP NREM
1 M 28 26.9 95 77 1 M 25 28.1 84 84
2 M 31 26.7 89 88 2 M 35 23 88 88
3 M 25 27.3 83 81 3 M 27 28 70 65
4 F 43 22.5 75 69 4 F 43 25.6 72 62
5 M 33 28 87 83 5 M 36 30 85 82
6 M 27 31 75 74 6 M 34 30 78 75
7 M 27 28.4 85 74 7 M 36 28 88 80
8 M 29 24.5 89 86 8 M 26 23 95 75
9 F 25 20 85 71 9 F 27 24 79 71
10 M 32 27 80 83 10 M 38 26 91 89
11 M 28 23.2 87 80 11 M 28 24.1 88 82
12 M 26 22.9 81 72
Mean 29.5 25.7 84.3 78.2 Mean 32.3 26.3 83.5 77.5
S.E. 1.4 0.9 1.7 6.2 S.E. 1.8 0.8 2.4 2.7BMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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home. The selection of the nCPAP pressure was based on
results from our pilot data, which showed that this level
of pressure effectively eliminated snoring in non-apneic
individuals. The purpose of the adaptation period was to
ensure that the subjects were able to tolerate nCPAP for a
minimum of 4 hours during completion of a third sleep
study (Trial 2). Nasal continuous positive airway pressure
was employed initially for 1 hour during the first night at
home. Thereafter, the duration of treatment was increased
by an additional hour each night until 4 hours of nCPAP
was tolerated. During the adaptation period subjects
received a phone call on days 3 and 6 to ensure that the
protocol was being followed. During all sleep studies sub-
jects were required to sleep in the supine position. The
subjects were monitored via an infrared camera to ensure
that this position was maintained throughout the sleep
period.
Nocturnal polysomnography
The sleep monitoring montage included an electroen-
cephalogram (C3/A2, C4/A1, O1/A2, O2/A1), electroocu-
logram, submental and tibialis anterior electromyogram
and an electrocardiogram. Abdominal movements were
monitored using a piezoelectric band (Pro-tech, Woodin-
ville, WA) and nasal pressure was measured using a pres-
sure transducer/airflow sensor (Pro-tech, Woodinville,
WA). Thus, breathing frequency was monitored breath-
by-breath. Oxygen saturation was measured using a pulse
oximeter (Biox 3700, Ohmeda Corp., Boulder, CO). Snor-
ing was measured using a microphone that was mounted
on the wall located adjacent to the subjects head. During
the preliminary study, blood pressure was monitored con-
tinuously and non-invasively from the third finger of the
left hand using a digital infrared photoplethysmograph
(Finapres 2300, Ohmeda Corp., Madison, WI). The accu-
racy of the blood pressure monitor was verified during
pre-sleep wakefulness and nocturnal awakenings by com-
paring its values to measurements made with a standard
mercury sphygmomanometer. To ensure that the moni-
toring site of the Finapres was adequately perfused with
blood throughout the evening, the operation of the Fin-
apres was discontinued consistently during rapid eye
movement sleep (REM) and at times during NREM sleep
if necessary. The total number of segments analyzed for
each subject represented on average 2.2 hours of data
obtained from stage II and SWS recorded over the entire
sleep period.
During sleep all physiological variables were analogue to
digitally converted at a sampling frequency of 200 Hz/
channel and input into a microcomputer using a commer-
cially available software package (Gamma, Version 4.0,
Astro-Med Inc., West Warwick, RI).
Data analysis (sleep variables)
Sleep was staged in 30-s epochs according to standard cri-
teria [11,12]. For each subject the total sleep period time
as well as the percent of total sleep time spent in a given
sleep stage was calculated. The total number of arousals,
apneas, hypopneas, snores, and the mean, minimal and
maximal oxygen saturation measured was calculated for
the total sleep time. An apnea was defined as the absence
of inspiratory airflow for a minimum of 10 s. The apnea
index was defined as the total number of apneas per hour
of sleep. A hypopnea was defined as greater than a 50 %
reduction in the flow signal lasting more than 10 s,
accompanied by a 2 % decrease in oxygen saturation. We
chose to employ a 2 % oxygen desaturation criteria (rather
than 3 or 4%) in order to ensure that snoring associated
with small changes in oxygen saturation were identified.
Based on the use of this criterion we reasoned that if the
number of breathing events was similar between snoring
and control subjects and less than 5, we could be reason-
ably confident that the subjects recruited for this study
were non-apneic. The hypopnea index was defined as the
total number of hypopneas per hour of sleep time. A
breath characterized by respiratory noises that registered
as an obvious deflection from the baseline of the snoring
channel was counted as a snore. In addition, the respira-
tory noises were subjectively determined to be snores by a
polysomnographic technologist monitoring an audio-vis-
ual system. We are confident that the sounds recorded
were associated with snoring since normal and heavy
breathing during wakefulness did not register on the
sound system while simulated snoring during wakeful-
ness was detected.
After staging the sleep studies completed during trial 1
and 2, we randomly selected a 15-minute snoring seg-
ment from NREM sleep (stage 2 or SWS) recorded
between midnight-2 am, 2–4 am and 4–6 am. Thus, 3–15
segments were selected from sleep studies completed dur-
ing Trials 1 and 2. The segments selected were devoid of
apneas, hypopneas and arousals. The snoring segments
(Trial 1) were identified as such if 67–100 % of the
breaths in a given segment were associated with snoring.
Three segments were selected from each study to ensure
that our findings reflected the impact of snoring on heart
rate variability throughout the night. However, we did not
report the results obtained from the snoring segments
selected from the beginning, middle and end of the night
separately. Although the data was analyzed originally in
this fashion, we found that our findings were not time
dependent, and thus the data from the three snoring seg-
ments were combined.
In addition to the snoring segments, we also analyzed one
15-minute non- snoring segment recorded during Trial 1.
In most subjects, only one 15-minute non-snoringBMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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segment in deep stage II or SWS was available for analysis.
We chose to analyze a non-snoring segment to compare
heart rate variability measures in snoring subjects during
non-snoring, which was independent of nCPAP applica-
tion, and snoring.
Data analysis (respiratory, cardiovascular and autonomic 
variables)
The number of snores and breaths was calculated for each
segment. Subsequently, the values calculated were divided
by the total segment time and reported as snoring fre-
quency (Sf) and breathing frequency (Bf) (snores/min and
breaths/min, respectively). To obtain a measure of SNSA
and PNSA the R waves of the electrocardiogram were iden-
tified using a threshold detection program. The time inter-
vals between the detected R waves (interbeat interval –
IBI) were plotted and the mean IBI was calculated for each
segment. Prior to frequency analysis, each 15-minute seg-
ment was divided into three 5-minute segments and the
interbeat intervals were re-sampled at 20 Hz, which pro-
vided 6000 equidistant data points per 5 minute segment
[13]. For each 5-min segment, an auto power spectrum
was created via a Fast Fourier transform of the interpo-
lated IBI data. The resulting spectrum was integrated and
areas associated with discrete frequency bands were deter-
mined. Power spectra within the 0.04–0.15 Hz range are
considered low frequency components (LF), whereas fre-
quencies of 0.15–0.4 Hz are defined as high frequency
components (HF). It is assumed that the power content of
the HF component represents PNSA whereas the power
content in the LF domain (0.04 – 0.15 Hz) represents
SNSA and PNSA at the sinus node [13,14]. The ratio of LF/
HF is assumed to be a measure of SNSA.
The absolute values of LF and HF were ln transformed so
that the data was normally distributed. Additionally, to
minimize the effect that changes in total power have on
the absolute values of the low and high frequency power,
the LF and HF values were normalized [13]. The presenta-
tion of LF and HF values in normalized units represents
the relative value of each power component in proportion
to the total power minus the very low frequency compo-
nent. Once the very low frequency component is sub-
tracted, the remaining power equals LF+HF. Thus,
normalized LF = LF ÷ (LF + HF)
normalized HF = HF ÷ (LF + HF)
The normalized units assume a balanced behavior of the
sympathetic (normalized LF) and parasympathetic nerv-
ous system (normalized HF values). Statistical analysis
was completed on both the ln transformed and normal-
ized values (see Statistical analysis below). However, for the
sake of clarity and based on the guidelines that LF and HF
values should be corrected for total power, the normal-
ized data was used as our point of reference in the discus-
sion (see critique of the methods for further discussion of
this point).
Statistical analysis
Unpaired t-tests were used to compare the anthropomet-
ric data between groups. A two-way analysis of variance in
conjunction with Student-Newman-Keuls post hoc test
was used to determine if differences in mean arterial
blood pressure existed between groups during wakeful-
ness and NREM sleep during completion of the prelimi-
nary study. The two factors in the design were "subject
population" (i.e. snorers versus controls) and "arousal
level" (i.e. wakefulness vs. sleep). A similar analysis was
employed to determine if differences in ln LF, ln HF, LF/
HF, normalized LF and normalized HF existed between
groups. The two factors in the design were "subject popu-
lation" (i.e. snorers versus controls) and "treatment" (i.e.
before versus after nCPAP treatment). This analysis was
also used to determine if differences in sleep architecture
existed between and within groups before and after
nCPAP treatment. A paired t-test was used to determine
whether ln LF, ln HF, LF/HF, normalized LF and normal-
ized HF during non-snoring in trial 1 was different from
measures obtained during snoring in trial 1. All values in
the tables are presented as means ± SE and the level of sig-
nificance chosen was p ≤ 0.05.
Results
Age, body mass index and blood pressure measured dur-
ing wakefulness and sleep throughout the preliminary
sleep study, were not significantly different between the
snoring and control groups (Table 1). Additionally, apnea
index, hypopnea index, arousal index and mean noctur-
nal oxygen saturation were not different between the snor-
ing and control groups during Trial 1 (Table 2). Similarly,
sleep efficiency and the percentage of time spent in a given
stage of NREM sleep did not vary significantly between
groups during completion of Trial 1 or Trial 2 (Table 2).
Moreover, the sleep architecture during Trial 2 did not dif-
fer significantly from that reported during Trial 1 within
both groups (Table 2).
Snoring episodes measured from the non-apneic snorers
were characterized by an average snoring frequency of
11.60 ± 0.43 snores per minute. In contrast, no snoring
was detected from the control group. The application of
nCPAP effectively eliminated snoring in all subjects.
Breathing frequency and heart rate were not significantly
different between or within groups for all conditions dur-
ing Trial 1 and 2 (Table 3). The two-way analysis of vari-
ance revealed that a significant "subject population" (i.e.
snorers versus controls) × "treatment" (i.e. before versusBMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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after nCPAP treatment) interaction existed for both ln HF
and normalized HF. Post-hoc analysis revealed that ln HF
and normalized HF recorded during snoring periods were
not significantly different from control during trial 1(i.e.
before nCPAP treatment) (ln HF - p = 0.47; normalized
HF - p = 0.34, respectively) (Table 3). In contrast, normal-
ized HF recorded during nCPAP treatment (i.e. trial 2) in
the snoring population was lower than normalized HF
recorded from the control population during nCPAP
treatment (p = 0.01) (Table 3). Moreover, ln HF and nor-
malized HF recorded during nCPAP treatment (i.e. trial 2)
in the snoring population was significantly less compared
to similar measures obtained from snoring periods during
trial 1 (ln HF - p < 0.0001; normalized HF - p = 0.001)
(Table 3).
A significant "subject population" (i.e. snorers versus con-
trols) × "treatment" (i.e. before versus after nCPAP treat-
ment) interaction also existed for normalized LF and LF/
HF. Post-hoc analysis showed that normalized LF and LF/
HF recorded during snoring was not significantly different
from control during trial 1 (normalized LF - p = 0.36; LF/
HF - p = 0.54, respectively) (Table 3). In contrast, normal-
ized LF and LF/HF recorded during nCPAP treatment (i.e.
trial 2) in the snoring population was greater than meas-
ures recorded from the control population during treat-
ment (normalized LF - p = 0.01; LF/HF - p = 0.01), and
from similar measures recorded from snoring periods dur-
ing trial 1 (normalized LF - p < 0.001; LF/HF - p < 0.001)
(Table 3).
Within the snoring group during trial 1, ln HF (p = 0.03)
and normalized HF (p = 0.01) were less and LF/HF (p =
0.02) and normalized LF (p = 0.01) were greater during
non-snoring as compared to snoring (Table 3).
Table 2: Sleep Measures
Control(n = 12) Snorer (n = 11)
NREM sleep 
(without CPAP) 
(Trial 1)
NREM sleep 
(with CPAP) 
(Trial 2)
NREM sleep 
(without CPAP) 
(Trial 1)
NREM sleep 
(with CPAP) 
(Trial 2)
Apnea index (apnea/hr) 0.38 ± 0.15 0.67 ± 0.34 1.19 ± 0.56 0.16 ± 0.07
Hypopnea index (hypopnea/hr) 1.80 ± 0.71 0.89 ± 0.29 2.14 ± 0.62 0.34 ± 0.19
Arousal index (arousals/hr) 12.87 ± 1.39 12.87 ± 1.02 14.11 ± 2.20 10.74 ± 1.83
Nocturnal Oxygen Saturation (%) 96.58 ± 0.23 96.7 ± 0.30 96.10 ± 0.39 96.40 ± 0.42
Sleep efficiency (%) 88.76 ± 3.62 88.09 ± 2.02 86.32 ± 2.18 83.73 ± 1.99
% of time in Stage I 11.29 ± 1.83 7.83 ± 0.90 7.22 ± 1.04 8.88 ± 1.57
% of time in Stage II 46.04 ± 1.42 45.53 ± 1.91 48.07 ± 2.58 48.48 ± 2.57
% of time in Slow Wave Sleep 22.45 ± 3.10 20.65 ± 1.42 21.95 ± 1.41 21.27 ± 2.36
Table 3: Autonomic measures obtained from controls and non-apneic snorers during wakefulness and non-rapid eye movement sleep
Control (n = 12) Snorer (n = 11)
NREM sleep
(without CPAP)
(Trial 1)
NREM sleep 
(with CPAP)
(Trial 2)
NREM sleep 
(without CPAP)
(snoring)
(Trial 1)
NREM sleep 
(without CPAP)
(non-snoring)
(Trial 1)
NREM sleep 
(with CPAP)
(Trial 2)
Heart rate (beats/min) 55.25 ± 1.53 54.58 ± 1.90 57.27 ± 1.45 55.18 ± 1.77 56.27 ± 1.74
Breathing Frequency 
(breaths/min)
14.89 ± 0.53 14.35 ± 0.46 13.85 ± 0.69 13.91 ± 0.53 14.23 ± 0.62
ln LF 7.24 ± 0.16 7.11 ± 0.13 7.68 ± 0.16 7.99 ± 0.27 7.41 ± 0.19
ln HF 7.99 ± 0.21 7.72 ± 0.19 8.19 ± 0.13 7.83 ± 0.18§ 7.40 ± 0.21§
LF/HF 0.57 ± 0.12 0.70 ± 0.14 0.69 ± 0.08 1.43 ± 0.29§ 1.20 ± 0.18*
HF (nu) 67.51 ± 3.60 64.44 ± 3.95 62.46 ± 2.60 46.71 ± 5.38§ 50.32 ± 4.18*
LF (nu) 34.27 ± 4.37 39.24 ± 5.01 36.61 ± 2.58 52.0 ± 5.26§ 48.79 ± 4.09*
* – significantly different from snorer – without CPAP – snoring; control – with CPAP
§ – significantly different from snorer – without CPAP – snoringBMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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Discussion
Summary of findings
Based on the normalized HF and LF values our major
findings are that PNSA and SNSA during snoring (i.e. Trial
1) was not significantly different from measures acquired
from non-snoring control subjects. However, PNSA was
decreased and SNSA was increased in the snoring popula-
tion compared to control when snoring was abolished
with nCPAP (i.e. Trial 2). Similarly, PNSA was less and
SNSA was greater when snoring was abolished (i.e. non-
snoring periods during trial 1 or during nCPAP applica-
tion in trial 2) compared to when it was present (trial 1)
within the snoring population. Finally, within the control
group PNSA and SNSA did not vary before and after treat-
ment with nCPAP.
Critique of the methods
Our subjects were exposed to nCPAP for a 7-day adapta-
tion period prior to completing Trial 2. This adaptation
period occurred after a baseline study was completed.
Consequently, the baseline and treatment study were not
randomized. Nevertheless, if the order of the trials
impacted on our measures we would expect that the
response to nCPAP application would have been similar
between groups since both groups were comparable (e.g.
healthy, no complaint of daytime sleepiness) in all
aspects with the exception of snoring. This was not the
case.
It is also unlikely that any differences observed between
groups during Trial 2 were a consequence of discomfort
associated with being unfamiliar with nCPAP treatment.
Both the snoring and control subjects adapted to the treat-
ment for a similar duration of time prior to participating
in Trial 2, and no significant differences in heart rate vari-
ability occurred within the control group when compar-
ing measures from Trial 1 and 2. Moreover, it is also
improbable that the differences observed were a conse-
quence of discrepancies in nCPAP compliance because,
based on subject self-report, this measure was similar
between groups. Although it is possible that some subjects
did not truthfully report their compliance, we believe it is
unlikely that healthy non-snorers and non-apneic snorers
would have tolerated nCPAP for at least 4 hours during
Trial 2 if they did not adhere to the protocol during the
adaptation period. The ability of the subject's to tolerate
nCPAP is supported by the measures of sleep architecture,
which were similar between trials 1 and 2. Lastly, it is
doubtful that the impact of nCPAP on cardiovascular
function [15], and consequently autonomic function, was
different between groups since the applied pressure was
identical (5 cmH2O in all cases) for both groups.
Heart rate variability has been used in numerous studies
to obtain non-invasive measures of SNSA (LF/HF and nor-
malized LF) and PNSA (HF and normalized HF). The
changes in the HF domain that we observed in our snor-
ing subjects were likely indicative of changes in PNSA
since this assumption has been well established by a
number of physiological investigations [13]. In contrast,
questions remain regarding the validity of LF/HF and nor-
malized LF as a non-invasive indicator of SNSA [14]. One
issue is that the LF/HF ratio assumes that HF in the
denominator (i.e. PNSA) cancels out the influence of
PNSA in the low frequency domain of the power spec-
trum, leaving the LF/HF ratio as a measure of SNSA.
Although we assume that LF/HF and normalized LF are
indicative of changes in SNSA we acknowledge that the
support for this assumption is equivocal. Nonetheless, we
have included this analysis along with the HF measures
for those who accept that LF/HF or normalized LF reflects
SNSA.
Investigators have shown that absolute values of LF and
HF are impacted by changes in total power [13]. Conse-
quently, it has been suggested that absolute LF and HF val-
ues should be normalized based on changes in total
power [13]. Based on this guideline, and for the sake of
clarity, we have used normalized LF and HF as our refer-
ence point in the subsequent discussion of the results.
Nevertheless, independent of whether one accepts that
normalization of our data is necessary, results obtained
from the normalized LF (i.e. SNSA) and HF (i.e. PNSA)
data are similar to the ratio of absolute LF/HF (i.e. SNSA)
and ln HF (i.e. PNSA).
Parasympathetic and sympathetic nervous system activity 
during snoring and non-snoring
Parasympathetic nervous system activity and SNSA during
snoring (i.e. trial 1) were not significantly different from
measures obtained from control subjects. This finding on
its own implies that snoring does not influence auto-
nomic function. However, our results showed that PNSA
was less and SNSA was greater in the snoring group com-
pared to control when snoring was abolished during trial
2. Similarly, PNSA was less and SNSA was greater in the
snoring group when snoring was abolished compared to
when snoring was present.
These latter two findings have three primary implications.
The first implication is that snoring may induce an acute
increase in PNSA and a decrease in SNSA, which may
mask the more deleterious effect that snoring has on auto-
nomic function. This would account for the similarities in
autonomic function observed between groups during trial
1 despite the differences that were present during trial 2.
The second implication is that the deleterious long-lasting
impact that snoring may have on autonomic function (see
Physiological Mechanisms for additional discussion on this
issue) is more evident during periods of non-snoring asBMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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indicated by the differences observed between the groups
during trial 2. The third implication is that short-term
nCPAP treatment did not eliminate this long-lasting
impact. Arguably, SNSA might have decreased and PNSA
increased because of nCPAP treatment. However, the lack
of response to treatment is not surprising since the sub-
jects did not receive treatment for a prolonged period with
respect to number of days and nighttime hours of
exposure.
Physiological mechanisms
We can only speculate on the mechanism responsible for
the potential decrease in SNSA and increase in PNSA that
occurs during snoring. Snoring is often associated with
increased airway resistance and the development of more
negative intrathoracic pressures [9]. Additionally, snoring,
or the application of high frequency, low amplitude pres-
sure oscillations (which simulates snoring), has been
associated with i) decreases in breathing frequency [5,6,9]
ii) increases in inspiratory time or inspiratory time/total
time ratio [5,6,9] and iii) increases in tidal volume
[5,7,8,16]. Moreover, breathing frequency, breathing pat-
tern or tidal volume are known to impact on measures of
heart rate variability [13,14]. Thus, it is possible that the
increase in HF that we observed during snoring, which
mirrors the amplitude of respiratory sinus arrhythmia,
was caused by changes in one or more of these variables.
Since snoring did not alter breathing frequency in our
study, we speculate that alterations in pattern and/or tidal
volume may have contributed to the increase in measures
of HF. More specifically, prolongation of inspiratory time
coupled with an increase in tidal volume may have led to
increased activation of pulmonary vagal afferents, which
have a profound influence on respiratory sinus arrhyth-
mia, and hence measures of HF. Additionally, activation
of pulmonary vagal afferents are known to inhibit SNSA
[17], thus the decrease in SNSA during snoring may have
been a consequence of this activation.
Since snoring itself was not accompanied by an increase in
SNSA or decrease in PNSA compared to control, the ques-
tion remains as to how snoring may ultimately result in
long-lasting increases in SNSA and/or decreases in PNSA
during non-snoring periods. There are at least three possi-
bilities. First, it is possible that snoring subjects participat-
ing in our study were genetically predisposed to a
reduction in PNSA and an increase in SNSA. Given our
experimental design, we cannot eliminate this possibility.
Future studies designed to examine autonomic nervous
system activity in non-apneic snorers, before and after
prolonged nCPAP treatment, may resolve whether the
changes in PNSA and SNSA we observed are an inherita-
ble trait.
Second, the impact of exposure to nCPAP treatment on
the non-apneic snorers compared to controls may have
been different (see Critique of methods for detailed discus-
sion on this issue). We consider this possibility highly
unlikely since the nCPAP pressure used and the duration
of application was similar for both populations. More
importantly, even in the absence of nCPAP treatment,
PNSA decreased and SNSA increased during non-snoring
compared to snoring (i.e. non-snoring vs. snoring in trial
1).
Third, we postulate that inputs activated during snoring
concurrently with vagal afferents may ultimately be
responsible for the long-lasting changes in PNSA and
SNSA activity that we observed. Thus, the influence of pul-
monary vagal afferents may predominate during snoring,
leading to a reduction in SNSA and an increase in PNSA.
However, we speculate that resistive loading and snoring
may concurrently enhance brainstem activity (i.e. the
reticular activating system), possibly via inputs from
mechanoreceptors [18], metabolic receptors [10,19], and
upper airway receptors [20,21], that eventually leads to
increases in SNSA and decreases in PNSA once snoring is
terminated. The possibility that snoring may influence
brainstem activation and ultimately autonomic nervous
system activity is supported by the findings of Lofaso and
colleagues [22]. These investigators showed in non-apneic
snorers that graded levels of arousal (based on various
changes in EEG characteristics) subsequent to termination
of snoring were associated with increases in heart rate and
blood pressure. More importantly for our findings, Lofaso
and colleagues [22] showed that even in the absence of
cortical arousal (no evidence of EEG changes) blood pres-
sure and heart rate were greater immediately after termi-
nation of snoring compared to measures obtained during
snoring [22]. The possibility that both the acute and long-
lasting impact of brainstem activation is masked during
snoring, when pulmonary vagal afferents are most influ-
ential, is supported by studies which have shown that
muscle sympathetic nervous system activity is profoundly
inhibited by the activation of pulmonary vagal afferents in
the presence of stimuli known to enhance SNSA [23].
Clinical implications
The upper airway resistance syndrome has been described
as a form of sleep disordered breathing that is character-
ized by repetitive increases in resistance in airflow within
the upper airway leading to brief cortical arousals and
daytime somnolence [24]. In contrast to this clinical
description, our subjects did not display excessive num-
bers of cortical arousal compared to control and did not
suffer from daytime somnolence. Nevertheless, despite
the absence of cortical arousal we showed that PNSA was
decreased and SNSA activity was increased during non-
snoring periods in non-apneic snorers compared to con-BMC Pulmonary Medicine 2005, 5:9 http://www.biomedcentral.com/1471-2466/5/9
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trol and during non-snoring periods compared to snoring
periods within the non-apneic population. The latter find-
ing is similar to results which showed that blood pressure
and heart rate increased at the termination of snoring
independent of cortical arousal [22,25]. Thus, alterations
in autonomic nervous system activity may lead to auto-
nomic and cardiovascular alterations in individuals with
increased airflow resistance independent of evidence of
cortical arousal. Moreover, our results suggest that altera-
tions in heart rate variability may precede changes in tra-
ditional markers of cardiovascular function (i.e. blood
pressure) in non-apneic snoring individuals. Given that
measures of heart rate variability have been shown to be
useful as a prognostic indicator of future cardiovascular
events [13,14,26-30] these measures may be useful in
determining whether normotensive individuals that snore
(or for that matter suffer from obstructive sleep apnea) are
at an increased risk for the development of hypertension
or cardiovascular disease. Whether the alterations that we
observed in our relatively young, healthy and predomi-
nantly male snoring population would benefit from long-
term treatment with nCPAP, or become more severe with
age and/or the presence of other co-morbid conditions
remains to be determined.
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